Suraksha Diagno. (SURAKSHA)

FairStock Score: 37/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 30.55% shows strong demand for healthcare services
• ROE of 17.71% and ROCE of 17.84% indicate solid capital efficiency
• Moderate debt-to-equity of 0.51 keeps financial risk in check
• Piotroski F-Score of 7/9 reflects generally healthy financials
• Promoter holding of 49% provides some alignment with minority shareholders

Concerns

• P/E of 42.45 and P/B of 7.23 leave no margin of safety
• Zero dividend yield means returns rely solely on capital appreciation
• PEG of 1.61 suggests growth is already priced in, while profit growth (22.28%) lags sales growth
• FairStock Score of 33/100 flags the stock as risky

AI Analysis

Let me look at Suraksha Diagno through the lens I've used for decades. A healthcare services firm in India, growing sales at 30.55% and profits at 22.28% – that's impressive. The latest quarter shows ₹78 Cr revenue and ₹7 Cr net profit, annualizing to roughly ₹312 Cr and ₹28 Cr. At ₹280.67, the market caps it at ₹1,414 Cr. That's a P/E of 42.45 – a hefty price indeed. Graham would remind me that paying 42 times earnings demands perfection. The PEG at 1.61 suggests the growth isn't cheap either. Business quality: ROE at 17.71% and ROCE at 17.84% are decent, and a debt-to-equity of 0.51 shows they aren't reckless. Piotroski F-Score of 7 points to solid financial health. But a P/B of 7.23 versus book value of ₹38.80 tells me the market is paying for future dreams, not today's assets. No dividend – so the only return is price appreciation, which is speculative. Promoter holding at 49% is okay, but not a fortress. I like the industry – healthcare services in India have tailwinds. But a moat? I don't see a wide one from the numbers alone. Diagnostic services can be competitive, with little pricing power. The FairStock score calls it risky at 33/100, and I agree. I'd wait for a margin of safety. At this price, I'm not a buyer. If the growth continues and the price becomes more reasonable, maybe. But for now, the risk-reward is not in my favor.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer